Bionik Laboratories Corp. (BNKL)

Bionik Laboratories Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Net Income	-4.95	-10.41	-13.62	-25.02	-10.56
Depreciation & Amortization	0.06	0.1	0.19	0.38	0.35
Asset Writedown & Restructuring Costs	-	5.22	7.18	14.02	-
Stock-Based Compensation	0.38	0.44	0.82	1.78	1.35
Provision & Write-off of Bad Debts	-	-	-	0.17	-0.02
Other Operating Activities	0.11	0.36	0.41	0.18	1.14
Change in Accounts Receivable	-0.18	0.18	0.4	0.51	-1.29
Change in Inventory	0.08	-0.54	0.33	-0.65	-0.17
Change in Accounts Payable	0.26	-0.15	-0.41	-0.29	0.42
Change in Unearned Revenue	0.08	-0	-0.04	0.15	0.35
Change in Other Net Operating Assets	0.78	0.66	0.12	-0.28	-0.8
Operating Cash Flow	-3.39	-4.15	-4.62	-9.06	-9.23
Capital Expenditures	-0.01	-0.01	-	-0.16	-0.1
Cash Acquisitions	-0.22	-	-	-	-
Investing Cash Flow	-0.22	-0.01	-	-0.16	-0.1
Short-Term Debt Issued	-	-	1.96	11.57	9.33
Long-Term Debt Issued	2.05	5.55	1	-	-
Total Debt Issued	2.05	5.55	2.96	11.57	9.33
Short-Term Debt Repaid	-	-	-	-0.52	-0.05
Total Debt Repaid	-	-	-	-0.52	-0.05
Net Debt Issued (Repaid)	2.05	5.55	2.96	11.05	9.27
Financing Cash Flow	2.05	5.55	2.96	11.05	9.27
Foreign Exchange Rate Adjustments	-0	-0.01	-	-	-
Net Cash Flow	-1.56	1.38	-1.66	1.82	-0.06
Free Cash Flow	-3.4	-4.16	-4.62	-9.22	-9.33
Free Cash Flow Margin	-188.12%	-326.59%	-387.44%	-428.32%	-287.56%
Free Cash Flow Per Share	-0.49	-0.71	-0.90	-2.07	-3.95
Levered Free Cash Flow	-1.58	-2.73	-3.58	-5.91	-13.58
Unlevered Free Cash Flow	-1.51	-2.21	-3.33	-5.79	-11.54
Change in Net Working Capital	-1.04	-0.24	0.49	0.82	7.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.